Leadership

Craig Anderson
Chief Executive Officer

Craig Anderson serves as the founder and Chief Executive Officer of Apogee. He is a seasoned executive, entrepreneur, and investor with 40 years of business experience. Mr. Anderson started his career working on Wall Street in the mid-1980s and did M&A and corporate finance at Merrill Lynch, Credit Suisse and other investment banking firms in New York City. Mr. Anderson was the founder and Chief Executive Officer of a health care services company that grew from three employees to approximately 2,000, culminating in a highly successful exit for himself and other investors. At Apogee, he leverages his extensive background in finance, operations, and corporate strategy to drive the company’s long-term vision, operational execution, and strategic growth initiatives. His leadership continues to shape Apogee’s evolution as an emerging innovator in the biotechnology industry.

Blair Hogg JD, LLM and MBA
Chief Operating Officer and General Counsel

Blair Hogg is the Chief Operating Officer and General Counsel of Apogee, bringing over 20 years of leadership spanning nexuses of law, finance, and corporate operations. With a background as both a seasoned attorney and financial strategist, Blair holds three graduate degrees JD, LLM, and MBA, credentials that underscore his unique ability to bridge legal expertise with business and financial acumen. Mr. Hogg has led complex and high-value transactions, navigated regulatory frameworks, and structured scalable organizations to support sustained growth. At Apogee, Mr. Hogg oversees all operational, financial and legal functions, ensuring the company’s expansion is executed with strategic discipline and operational rigor.

Joshi Ramanjulu, PhD
Chief Scientific Officer

Dr. Joshi Ramanjulu serves as the Chief Scientific Officer of Apogee, bringing over 25 years of drug discovery and early development experience, primarily from his tenure at GlaxoSmithKline (GSK), where he held senior scientific leadership roles. A highly accomplished and widely respected scientific executive, Dr. Ramanjulu has successfully led large, cross-functional teams across the full continuum of R&D, from target identification through development candidate selection and FTIH recommendations. His work spans multiple therapeutic areas and is distinguished by a modality-agnostic approach, including small molecules, biologics, and novel therapeutic platforms. In addition to his deep scientific and operational expertise, he has played an instrumental role in implementing business development strategies that have expanded and accelerated research pipelines through strategic external partnerships. His contributions to the field are reflected in a substantial portfolio of peer-reviewed publications.

Katherine Radek, PhD
Senior Director of Biology

Dr. Katherine Radek serves as the Senior Director of Biology at Apogee, bringing over 16 years of expertise in immunology, host defense mechanisms, and preclinical drug discovery. She has built a distinguished career advancing therapeutic innovation at the interface of fundamental biology and translational medicine. Prior to joining Apogee, Dr. Radek held leadership roles at GlaxoSmithKline (GSK), where she directed cross-functional teams in the discovery and development of novel therapeutics across immunology and neurodegeneration. Her scientific contributions span the full spectrum of early R&D, including target validation, lead optimization, and the advancement of pipeline assets through key preclinical milestones. With a deep commitment to translational science, Dr. Radek ensures that Apogee’s biology programs are underpinned by rigorous mechanistic insight and are strategically aligned for successful progression toward clinical development. Her leadership strengthens the company’s ability to deliver scientifically grounded, high-potential therapies to address unmet medical needs.

Craig Volker, PhD
Director of Translational Medicine

Dr. Craig Volker serves as the Director of Translational Biology at Apogee and has a distinguished career that spans 25 years in drug discovery and development, primarily at GlaxoSmithKline (GSK). An accomplished and award-winning scientist, Dr. Volker has led high-performing teams across biology, informatics, and interdisciplinary research, contributing significantly to the advancement of both early-stage and clinical programs. His scientific leadership has been instrumental in the identification and validation of therapeutic targets across a wide array of disease areas, demonstrating a deep understanding of the complex interface between discovery science and clinical application. In addition to his research accomplishments, Dr. Volker has played a critical role in strategic decision-making, serving as a key member of cross-functional teams responsible to evaluate external innovation and partnership opportunities. At Apogee, he leads the company’s translational biology efforts, ensuring that foundational laboratory insights are effectively translated into viable clinical candidates, and that scientific rigor is maintained throughout the transition from discovery to development.